От глубокого инфильтративного эндометриоза к эндометриоз-ассоциированному раку: современные аспекты дифференциальной диагностики

Глубокий инфильтративный эндометриоз является социально значимой проблемой, значительно ухудшающей качество жизни пациенток вследствие хронического болевого синдрома и высокого риска бесплодия. В последнее время все чаще появляются данные о злокачественной трансформации заболевания с формированием очагов малигнизации преимущественно яичниковой, а также внеяичниковой локализации. Сходство клинических проявлений, морфологических характеристик и молекулярных изменений доброкачественных и злокачественных форм существенно затрудняет дифференциальную диагностику. В статье обобщены современные представления о критериях разграничения глубокого инфильтративного эндометриоза и эндометриоз-ассоциированного рака. Подчеркивается ограниченность доказательной базы и необходимость разработки стандартизированных интегративных подходов для повышения точности диагностики и стратификации онкологического риска в данной категории пациенток.

1. Steinbuch S.C., Lüß A.-M., Eltrop S. et al. Endometriosis-associated ovarian cancer: from molecular pathologies to clinical relevance. Int J Mol Sci. 2024;25(8):4306. https://doi.org/10.3390/ijms250843062.

2. Suda K., Cruz Diaz L.A., Yoshihara K. et al. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. 2020;111(8):3000–9. https://doi.org/10.1111/cas.14507.

3. Kawahara N., Miyake R., Yamanaka S., Kobayashi H. A novel predictive tool for discriminating endometriosis associated ovarian cancer from ovarian endometrioma: the R2 predictive index. Cancers. 2021;13(15):3829. https://doi.org/10.3390/cancers13153829.

4. Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Research. 2019;8:F1000 Faculty Rev-529. https://doi.org/10.12688/f1000research.14817.1.

5. International working group of AAGL, ESGE, ESHRE and WES, Vermeulen N., Abrao M.S., Einarsson J.I. et al. Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. Human Reprod Open. 2021;2021(4):hoab025. https://doi.org/10.1093/hropen/hoab025.

6. D'Alterio M.N., D'Ancona G., Raslan M. et al. Management challenges of deep infiltrating endometriosis. Int J Fertil Steril. 2021;15(2):88–94. https://doi.org/10.22074/IJFS.2020.134689.

7. Abike F., Tanoglu F.B., Sidar G. Deep pelvic endometriosis: clinical features, diagnosis, and treatment – a comprehensive review. Arch Gynecol Obstet. 2025;312(6):1857–69. https://doi.org/10.1007/s00404-025-08187-0.

8. Freytag D., Peters G., Mettler L. et al. Perioperative considerations in the treatment of endometriosis. J Turk Ger Gynecol Assoc. 2021;22(4):319–25. https://doi.org/10.4274/jtgga.galenos.2021.2021.0017.

9. Guerriero S., Condous G., van den Bosch T. et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016;48(3):318–32. https://doi.org/10.1002/uog.15955.

10. Alkatout İ., Meinhold-Heerlein I., Keckstein J., Mettler L. Endometriosis: a concise practical guide to current diagnosis and treatment. J Turk Ger Gynecol Assoc. 2018;19(3):173–5. https://doi.org/10.4274/jtgga.2018.0026.

11. Li B., Wang Y., Wang Y. et al. Deep infiltrating endometriosis malignant invasion of cervical wall and rectal wall with Lynch syndrome: a rare case report and review of literature. Front Oncol. 2022;12:832228. https://doi.org/10.3389/fonc.2022.832228.

12. Shi S., Huang C., Tang X. et al. Identification and verification of diagnostic biomarkers for deep infiltrating endometriosis based on machine learning algorithms. J Biol Eng. 2024;18(1):70. https://doi.org/10.1186/s13036-024-00466-9.

13. Luna Russo M.A., Chalif J.N., Falcone T. Clinical management of endometriosis. Minerva Ginecol. 2020;72(2):106–18. https://doi.org/10.23736/S0026-4784.20.04544-X.

14. Machairiotis N., Vasilakaki S., Kouroutou P. Natural products: potential lead compounds for the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2020;245:7–12. https://doi.org/10.1016/j.ejogrb.2019.11.019.

15. Melki E. Endometriosis treatment with shock waves: A novel approach. Med Hypotheses. 2019;124:114–7. https://doi.org/10.1016/j.mehy.2019.02.022.

16. Mikocka-Walus A., Druitt M., O'Shea M. et al. Yoga, cognitive-behavioural therapy versus education to improve quality of life and reduce healthcare costs in people with endometriosis: a randomised controlled trial. BMJ Open. 2021;11(8):e046603. https://doi.org/10.1136/bmjopen-2020-046603.

17. Gonçalves A.V., Barros N.F., Bahamondes L. The practice of hatha yoga for the treatment of pain associated with endometriosis. J Altern Complement Med. 2017;23(1):45–52. https://doi.org/10.1089/acm.2015.0343.

18. Kajiyama H., Suzuki S., Yoshihara M. et al. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186–92. https://doi.org/10.1016/j.freeradbiomed.2018.12.015.

19. Бегович Ё., Солопова А.Г., Бицадзе В.О. и др. Актуальные вопросы этиопатогенеза, лечения и реабилитации эндометриоз-ассоциированного рака. Акушерство, Гинекология и Репродукция. 2021;15(3):287–94. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.206.

20. Barnard M.E., Farland L.V., Yan B. et al. Endometriosis typology and ovarian cancer risk. JAMA. 2024;332(6):482–9. https://doi.org/10.1001/jama.2024.9210.

21. Koppolu A., Maksym R.B., Paskal W. et al. Epithelial cells of deep infiltrating endometriosis harbor mutations in cancer driver genes. Cells. 2021;10(4):749. https://doi.org/10.3390/cells10040749.

22. Kvaskoff M., Mahamat-Saleh Y., Farland L.V. et al. Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):393–420. https://doi.org/10.1093/humupd/dmaa045.

23. Dawson A., Fernandez M.L., Anglesio M. et al. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience. 2018;12:803. https://doi.org/10.3332/ecancer.2018.803.

24. Mafra F., Mazzotti D., Pellegrino R. et al. Copy number variation analysis reveals additional variants contributing to endometriosis development. J Assist Reprod Genet. 2017;34(1):117–24. https://doi.org/10.1007/s10815-016-0822-1.

25. Anglesio M.S., Papadopoulos N., Ayhan А. et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835–48. https://doi.org/10.1056/NEJMoa1614814.

26. Kordowitzki P., Mechsner S., Sehouli J. ARID1a gene as a potential early marker to tackle endometriosis-associated ovarian cancer. Aging Dis. 2023;15(6):2331–3. https://doi.org/10.14336/AD.2023.1109.

27. Ioannidou A., Sakellariou M., Sarli V. et al. New evidence about malignant transformation of endometriosis – a systematic review. J Clinical Med. 2025;14(9):2975. https://doi.org/10.3390/jcm14092975.

28. Bartiromo L., Schimberni M., Villanacci R. et al. A systematic review of atypical endometriosis-associated biomarkers. Int J Mol Sci. 2022;23(8):4425. https://doi.org/10.3390/ijms23084425.

29. Guidozzi F. Endometriosis-associated cancer. Climacteric. 2021;24(6):587–92. https://doi.org/10.1080/13697137.2021.1948994.

30. Tang L., Bian C. Research progress in endometriosis-associated ovarian cancer. Front Oncol. 2024;14:1381244. https://doi.org/10.3389/fonc.2024.1381244.

31. Katsumata N., Yasuda M., Isonishi S. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6. https://doi.org/10.1016/S1470-2045(13)70363-2.

32. Clamp A.R., James E.C., McNeish I.A. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol.. 2022;23(7):919–30. https://doi.org/10.1016/S1470-2045(22)00283-2.

33. Harter P., Sehouli J., Lorusso D. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–32. https://doi.org/10.1056/NEJMoa1808424.

34. Villarejo Campos P., Sánchez García S., Amo-Salas M. et al. Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: a Randomized Phase III Clinical Trial (HIPECOVA). Curr Oncol. 2024;31(2):660–71. https://doi.org/10.3390/curroncol31020048.

35. Adilbayeva A., Kunz J. Pathogenesis of endometriosis and endometriosis-associated cancers. Int J Mol Sci. 2024;25(14):7624. https://doi.org/10.3390/ijms25147624.

36. Liu J., Ma Y., Jiang W., Xie P. Research progress on correlative prediction factors and prediction models of endometriosis associated ovarian carcinoma. Medicine. 2024;103(42):e40131. https://doi.org/10.1097/MD.0000000000040131.

37. Dochez V., Caillon H., Vaucel E. et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. https://doi.org/10.1186/s13048-019-0503-7.

38. Tavares V., Marques I.S., Melo I.G. et al. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25(3):1845. https://doi.org/10.3390/ijms25031845.

39. Bi Q., Wang Y., Deng Y. et al. Different multiparametric MRI-based radiomics models for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study. Front Oncol. 2022;12:939930. https://doi.org/10.3389/fonc.2022.939930.

40. Tanase Y., Kawaguchi R., Takahama J., Kobayashi H. Factors that differentiate between endometriosis-associated ovarian cancer and benign ovarian endometriosis with mural nodules. Magn Reson Med Sci. 2018;17(3):231–7. https://doi.org/10.2463/mrms.mp.2016-0149.

41. Wu L.M., Li J.K. Malignant transformation of deep infiltrating endometriosis with invasion of the rectum in a 34-year-old woman. Asian J Surg. 2023;46(7):2999–3000. https://doi.org/10.1016/j.asjsur.2023.02.024.

42. Bayrak R., Yenidünya S., Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011;207(3):156–60. https://doi.org/10.1016/j.prp.2010.12.005.